Literature DB >> 34184190

Malignancy Risk of Immunoglobin G4-Related Disease: Evidence from a Large Cohort Multicenter Retrospective Study.

Yanying Liu1, Jiangnan Fu2, Xiaoran Ning3, Huijuan Li4, Xiangbo Ma4, Kunkun Wang5, Wenjie Bian2, Yuxin Zhang2, Guangyan Yu6, Zhanguo Li7.   

Abstract

INTRODUCTION: The aim of this work was to evaluate the prevalence of malignancies in a multicenter cohort of Chinese patients with immunoglobulin G4-related disease (IgG4-RD) and to identify the related risk factors of malignancy in IgG4-RD patients.
METHODS: We retrospectively analyzed 602 IgG4-RD patients who were recruited in five medical centers from 2009 to 2020. Standardized prevalence ratios (SPRs) against the general Chinese population were calculated along with 95% confidence intervals (CIs). We identified the risk factors of malignancy in IgG4-RD and calculated the odds ratios (ORs) of different factors. We then developed and validated a prediction model for malignancy risk of IgG4-RD based on our cohort.
RESULTS: We observed a significantly increased prevalence of total malignancies in this cohort compared to the general Chinese population (SPR 8.66 [95% CI 5.84, 12.31]). Logistic regression analysis indicated that eosinophil percentage (OR 1.096 [95% CI 1.019-1.179], P = 0.016), serum albumin-to-globulin ratio (AGR) (OR 0.185 [95% CI 0.061-0.567], P = 0.002) and autoimmune pancreatitis (OR 2.400 [95% CI 1.038-5.549], P = 0.041) were three potential risk factors of malignancy in IgG4-RD patients. Four predictors were included in our final prediction model: age at IgG4-RD diagnosis, eosinophil percentage, AGR and autoimmune pancreatitis. The nomogram performed well in the internal validation cohort, with a concordance index (C-index) of 0.738.
CONCLUSIONS: A significantly increased prevalence of total malignancies was observed in our multicenter cohort. Eosinophil percentage and autoimmune pancreatitis are risk factors, whereas AGR is negatively associated with malignancy in IgG4-RD. A prediction model for malignancy risk of IgG4-RD was first developed and validated in our study.

Entities:  

Keywords:  IgG4-related disease; Malignancy; Prediction model; Risk factors

Year:  2021        PMID: 34184190     DOI: 10.1007/s40744-021-00326-8

Source DB:  PubMed          Journal:  Rheumatol Ther        ISSN: 2198-6576


  42 in total

Review 1.  Consensus statement on the pathology of IgG4-related disease.

Authors:  Vikram Deshpande; Yoh Zen; John Kc Chan; Eunhee E Yi; Yasuharu Sato; Tadashi Yoshino; Günter Klöppel; J Godfrey Heathcote; Arezou Khosroshahi; Judith A Ferry; Rob C Aalberse; Donald B Bloch; William R Brugge; Adrian C Bateman; Mollie N Carruthers; Suresh T Chari; Wah Cheuk; Lynn D Cornell; Carlos Fernandez-Del Castillo; David G Forcione; Daniel L Hamilos; Terumi Kamisawa; Satomi Kasashima; Shigeyuki Kawa; Mitsuhiro Kawano; Gregory Y Lauwers; Yasufumi Masaki; Yasuni Nakanuma; Kenji Notohara; Kazuichi Okazaki; Ji Kon Ryu; Takako Saeki; Dushyant V Sahani; Thomas C Smyrk; James R Stone; Masayuki Takahira; George J Webster; Motohisa Yamamoto; Giuseppe Zamboni; Hisanori Umehara; John H Stone
Journal:  Mod Pathol       Date:  2012-05-18       Impact factor: 7.842

2.  Conditions associated with polyclonal hypergammaglobulinemia in the IgG4-related disease era: a retrospective study from a hematology tertiary care center.

Authors:  Eric J Zhao; Mollie N Carruthers; Charles H Li; Andre Mattman; Luke Y C Chen
Journal:  Haematologica       Date:  2019-06-27       Impact factor: 9.941

Review 3.  Polyclonal hypergammaglobulinaemia: assessment, clinical interpretation, and management.

Authors:  Eric J Zhao; Catherine V Cheng; Andre Mattman; Luke Y C Chen
Journal:  Lancet Haematol       Date:  2021-05       Impact factor: 18.959

4.  Association of IgG4-Related Disease With History of Malignancy.

Authors:  Zachary S Wallace; Carly J Wallace; Na Lu; Hyon K Choi; John H Stone
Journal:  Arthritis Rheumatol       Date:  2016-09       Impact factor: 10.995

Review 5.  IgG4-related disease and the kidney.

Authors:  Frank B Cortazar; John H Stone
Journal:  Nat Rev Nephrol       Date:  2015-06-30       Impact factor: 28.314

6.  Malignancies in Korean patients with immunoglobulin G4-related disease.

Authors:  Sung Soo Ahn; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  Int J Rheum Dis       Date:  2017-05-22       Impact factor: 2.454

7.  Risk of malignancies in IgG4-related disease.

Authors:  Motohisa Yamamoto; Hiroki Takahashi; Tetsuya Tabeya; Chisako Suzuki; Yasuyoshi Naishiro; Keisuke Ishigami; Hidetaka Yajima; Yui Shimizu; Mikiko Obara; Hiroyuki Yamamoto; Tetsuo Himi; Kohzoh Imai; Yasuhisa Shinomura
Journal:  Mod Rheumatol       Date:  2011-09-06       Impact factor: 3.023

Review 8.  IgG4-related hepatobiliary disease: an overview.

Authors:  Emma L Culver; Roger W Chapman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-14       Impact factor: 46.802

Review 9.  IgG4-related disease: what a hematologist needs to know.

Authors:  Luke Y C Chen; Andre Mattman; Michael A Seidman; Mollie N Carruthers
Journal:  Haematologica       Date:  2019-01-31       Impact factor: 9.941

10.  Malignancy and IgG4-related disease: the incidence, related factors and prognosis from a prospective cohort study in China.

Authors:  Hanqi Tang; Huaxia Yang; Panpan Zhang; Di Wu; Shangzhu Zhang; Jiuliang Zhao; Linyi Peng; Hua Chen; Yunyun Fei; Xuan Zhang; Yan Zhao; Xiaofeng Zeng; Fengchun Zhang; Wen Zhang
Journal:  Sci Rep       Date:  2020-03-18       Impact factor: 4.379

View more
  2 in total

Review 1.  Bibliometric analysis of IgG4-related disease research from 2003 to 2022 based on Web of Science Core Collection Databases.

Authors:  Zhijie Lv; Li Wu; Yan Lu; Shan Liu; Qiushuang Li
Journal:  Clin Rheumatol       Date:  2022-09-19       Impact factor: 3.650

2.  Comment on "The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis" by Yu et al.

Authors:  James Cheng-Chung Wei; Liyun Zhang; Hann-Ziong Yueh
Journal:  Arthritis Res Ther       Date:  2022-05-24       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.